Clinical Trial Update: A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase I/II trial of Abiraterone Acetate plus BEZ235 in metastatic castration-resistant prostate cancer was terminated, with results posted in 2018…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• BEZ235 (dactolisib)

Snippet

Sponsor: Charles Ryan | Conditions: Castrate-resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-03-27